37000 GRAND RIVER AVE., FARMINGTON HILLS, MI
Investor Presentation
Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
Earnings Release
Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
R&D Science Forum June 16, 2026 | 10:00 AM – 12:00 PM ET
Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Opus Genetics Stockholders Elect Nine Directors and Ratify Auditor
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Additional Proxy Soliciting Materials
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Correspondence